Xeris Biopharma (XERS) to Release Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $58.54 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Xeris Biopharma Stock Down 3.7 %

Shares of XERS stock opened at $3.69 on Tuesday. The stock has a market cap of $550.11 million, a price-to-earnings ratio of -8.20 and a beta of 2.61. The business’s fifty day moving average is $3.53 and its 200 day moving average is $3.22. Xeris Biopharma has a twelve month low of $1.69 and a twelve month high of $4.10.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on XERS shares. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research report on Monday, November 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Finally, HC Wainwright boosted their price objective on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a report on Monday, November 11th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.